Prothena (NASDAQ:PRTA) used its fourth-quarter and full-year 2025 results call to highlight partner-driven clinical momentum, updates from its wholly owned preclinical portfolio, and a sharper cash ...
These biotech companies have catalysts ahead.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results